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Abstract
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Objective—Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble Blymphocyte stimulator and was approved by the FDA for treatment of adults with systemic lupus
erythematosus (SLE). This study evaluates the use and efficacy of belimumab in academic SLE
practices.
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Methods—Invitations to participate and complete a one-page questionnaire for each patient
prescribed belimumab were sent to 16 physicians experienced in SLE Phase III clinical trials. The
outcome was defined as the physician’s impression of improvement in the initial manifestation(s)
being treated without worsening in other organ systems.
Results—Of 195 patients treated with belimumab at 10 academic centers, 96% were on
background medications for SLE at initiation of belimumab, with 74% on corticosteroids. The
main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic
activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients on belimumab for
at least 6 months, 51% responded clinically and 67% had ≥25% improvement in laboratory values.
While numbers are limited, black patients showed improvement at 6 months. In a subset of 39
patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued
corticosteroids.

Author Manuscript

Conclusion—Our data demonstrate favorable clinical and laboratory outcomes in patients with
SLE at 6 months across all racial and ethnic groups, with similar improvement seen among
patients with childhood-onset SLE.
Keywords
belimumab; lupus treatment; childhood-onset lupus

INTRODUCTION

Author Manuscript

Systemic lupus erythematosus (SLE) is a chronic, multi-system, autoimmune disease of
unknown etiology with a heterogeneous range of clinical and serological manifestations.
Adding to the complexity of SLE is the unpredictability of flares, or periods of increased
inflammatory disease activity, as well as the accrual of organ damage (1, 2). “Standard of
care” therapy for SLE includes antimalarials, corticosteroids, immunosuppressives, and
cytotoxic agents. These treatments often result in undesired long-term adverse effects and
organ damage that are unavoidable due to the essential role of these medications in SLE
treatment.
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Although the etiology of SLE remains largely unknown, an increased understanding of its
immunopathogenesis, in particular, B cell-specific mechanisms, has allowed for a focus on
targeted immunotherapy. This led to the development and testing of belimumab (Benlysta®)
for SLE and subsequent approval in 2011 by the US Food and Drug Administration for the
treatment of adults with active SLE (3). Belimumab is a fully-human, recombinant inhibitor
of soluble B lymphocyte stimulator (BLyS) and neutralizes a key cytokine that plays a major
role in B cell differentiation, proliferation, and survival (4–6). Two randomized, doubleblind, placebo-controlled, multi-center Phase III trials (BLISS-52 and BLISS-76)
demonstrated improvement in disease activity in patients treated with belimumab and
standard of care SLE therapy compared to those treated with placebo and standard therapy
alone (7, 8).
Since the initial belimumab clinical trials, the post-approval clinical experience of patients
receiving belimumab at 10mg/kg/dose every 4 weeks along with standard SLE therapy as
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well as the practice patterns of academic physicians in clinical settings has received
increased attention. In addition, the data are scarce on the use of belimumab in patients with
childhood-onset SLE. Childhood-onset is diagnosed prior to the patient’s 18th birthday and
accounts for up to 20% of all SLE patients (9). When compared to adult-onset SLE,
childhood-onset SLE has increased disease activity, morbidity, and mortality, often requiring
earlier and more aggressive treatment with immunosuppressive medications for disease
control (10–16).
Due to the multitude of challenging characteristics of successful trials, including identifying
meaningful outcomes and appropriate patient populations, post-marketing observational
studies are often useful in providing supplementary information to trials. The objective of
this multi-center study was to analyze the experience with belimumab in academic clinical
practices.

Author Manuscript

MATERIALS AND METHODS
Study Design

Author Manuscript

This is a prospective, multicenter, observational study conducted in 10 large academic SLE
clinical practices, 9 of whom were in the United States. Approvals to conduct this study
were obtained from the Institutional Review Boards of the respective institutions. Sixteen
adult rheumatologists experienced in Phase III SLE clinical trials were invited to participate,
10 of whom accepted the invitation and completed repeat assessments of SLE patients
treated with belimumab as part of their standard of care. Assessments consisted of a singlepage questionnaire per patient completed every three months. All investigators who agreed
to participate were located in countries where belimumab has received regulatory agency
approval (United States and Sweden).
Inclusion and exclusion criteria
All patients were required to have a diagnosis of SLE, have met at least 4 of 11 American
College of Rheumatology (ACR) or Systemic Lupus International Collaborative Clinics
(SLICC) classification criteria (17, 18), and have started treatment with belimumab after
approval by regulatory agencies. Exclusion criteria included patients who had previously
participated in the belimumab clinical trials, and those who met fewer than 4 ACR
classification criteria. We also excluded patients from this study who had severe renal or
neuropsychiatric involvement.
Questionnaire

Author Manuscript

The single-page questionnaire included basic demographic information (e.g., age, sex, race/
ethnicity), SLE data (including disease duration, year of diagnosis, serologies, clinical
manifestation(s) of lupus, and concomitant medications), and belimumab information
(including start date, clinical response, laboratory response, side effects, and reasons for
discontinuation of belimumab). The questionnaires were completed every three months by
the treating physician to capture long-term clinical patterns of belimumab.
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All investigators adhered to the guidelines for 50% improvement as defined by the
Responder Index for Lupus Erythematosus (RIFLE) and British Isles Lupus Assessment
Group (BILAG), including clinical improvement and at least intent to decrease therapy (19,
20) without worsening in any organ systems. This was further defined as the treating
physician’s impression of a ≥50% improvement in the initial manifestation(s) being treated
and the ability to taper existing steroid dose by at least 25% of the initial dose for those
patients who were on steroids at initiation of belimumab. Anti-dsDNA positivity was defined
as having an anti-dsDNA level above the normal range at the local laboratory; similarly, low
complement was defined as having a C3 and/or C4 level below the normal range at the local
laboratory. Laboratory response was defined as a ≥25% improvement in the levels of C3, C4,
and/or a 25% decrease in anti-dsDNA antibody levels. Responders were those patients who
achieved the outcome measures as defined above; non-responders were those who did not.
Moreover, to be classified as a responder, there could be no worsening in other organ
systems.
Data Analysis
Descriptive statistics were used to evaluate the baseline characteristics of enrolled patients
using Graphpad Prism 6 (La Jolla, CA). Every three months, clinical and laboratory
response data were evaluated using t-tests and chi-square tests where appropriate.

RESULTS
Demographics

Author Manuscript

A total of 195 SLE patients treated with belimumab were enrolled, most of whom were
female (Table 1), with 29% black and 11% Hispanic. The average disease duration at
initiation of belimumab was 11.9 ± 8.1 years among the 151 patients with data regarding the
date of diagnosis available. Four patients were anti-nuclear antibody (ANA) negative.
Concomitant Medications
Of 195 patients, 7 adult-onset SLE patients were not taking any background SLE
medications at the time of belimumab initiation (Table 1), while 73% were on antimalarials,
and 74% were on corticosteroids. Of those on corticosteroids at initiation of belimumab, the
mean daily prednisone equivalent dose was 12.2mg/day (range 5 to 50mg/day). The majority
of patients (66%) were on immunosuppressive medications, with 21% on azathioprine and
34% on mycophenolate mofetil. No patients were concurrently receiving cyclophosphamide
or rituximab.
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Clinical Manifestations
At initiation of belimumab, the breakdown of clinical manifestations requiring treatment is
detailed in Table 1. The main clinical manifestations driving treatment were musculoskeletal
and mucocutaneous. Proteinuria was present in 11% of patients at the time of initiation of
belimumab.
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Belimumab was used off-label in 7 patients who were not on any background SLE
medications at the time of initiation, though 4 were on daily oral corticosteroids. The clinical
manifestations driving treatment were rash, arthritis and serositis. One patient was started on
belimumab for constitutional symptoms.
Fifteen patients were on anti-malarial treatment alone at the time of initiation of belimumab.
The main clinical manifestations driving treatment were rash, arthritis and serositis. Four
patients had hematological abnormalities, and two patients had constitutional symptoms.
Response to belimumab

Author Manuscript

At three months of belimumab treatment, 52% of patients clinically responded to belimumab
with improvement in the clinical manifestations driving initiation of belimumab (Figure 1).
At 3 months, 61% of patients started on belimumab for arthritis, 43% of patients with rash,
and 78% of patients with renal manifestations responded to therapy. At six months, data on
120 patients were available for analysis and showed 51% with clinical response. Responders
included 46% of patients with arthritis, 52% of patients with rash, and 57% of patients with
renal manifestations. The mean daily prednisone equivalent dose of corticosteroids
decreased to 9.3mg/day at 6 months from 12.2mg/day at baseline (p=NS).
At 3 months after initiation of belimumab, 68 of 103 patients (66%) had at least a 25%
increase in C3 values, and 35 of 72 patients (48%) had a 25% decrease in anti-dsDNA
values (Figure 1). This was maintained at 6 months, with 67% of patients demonstrating at
least 25% decrease in anti-dsDNA values. No significant differences were found in either
clinical or laboratory response rates in patients on different background immunosuppressive
medications (data not shown).
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Elderly Patients
Four patients were over 65 years of age at the time of initiation of belimumab therapy, and it
was initiated off-label. The clinical manifestations driving treatment were arthritis in all
patients and serositis in 2 patients. All patients were on daily oral prednisone at the time of
initiation of therapy with a range of 3 to 11mg/day. Only one patient was on another
immunosuppressive (mycophenolate mofetil), and no patients were on hydroxychloroquine.
Two patients had elevated levels of anti-dsDNA antibodies, but no patients had
hypocomplementemia. At 6 months, only one patient responded to therapy with resolution
of arthritis and serositis and all patients remained on the same baseline dose of prednisone.
Black Patients

Author Manuscript

Data on blacks, although limited, show a similar pattern of improvement. Of 57 black
patients, 4 were on no background medications at the start of belimumab. There were 17
patients on corticosteroids. The major clinical manifestations for initiation of belimumab
were arthritis, inability to taper steroids, and rash. When compared to the non-black patients
in the cohort, black patients showed a higher clinical response rate to belimumab at 3
months (82% vs 45%, p=0.0001). Data were available for 21 black patients on belimumab
for 6 months; 67% responded to belimumab.
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Twelve patients in the cohort had a history of lupus nephritis and proteinuria ≥1000mg/24
hours at the time of initiation of belimumab. Follow-up data were available on 6 of these
patients; 3 patients had ≥ 50% improvement in proteinuria after initiation of belimumab.
Childhood-onset SLE
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A subset of 39 patients treated with belimumab were diagnosed with SLE prior to their 18th
birthday, most of whom were female (Table 2), with a mean disease duration of 12±8 years
at initiation of belimumab. Four patients were under 18 years of age at the time of initiation
of belimumab therapy, and it was initiated off-label. All childhood-onset SLE patients were
on background medications at the start of belimumab, including 82% on corticosteroids with
a mean daily prednisone equivalent dose of 17mg, compared to 72% of adult-onset SLE
patients on corticosteroids with a mean daily dose of 11mg (p<0.01). The main clinical
manifestations treated in childhood-onset SLE patients were the inability to taper
corticosteroids, musculoskeletal, and mucocutaneous. In the 4 patients under 18 years of age
who were treated off-label, the clinical manifestations driving decision to treat were rash in 2
patients, thrombocytopenia in 1, and inability to taper steroids in all four patients. Clinical
improvement was detected at as early as 3 months after initiation of therapy in 41% of
childhood-onset SLE patients. At six months of treatment with belimumab, 65% of
childhood-onset SLE patients had clinically responded compared to 45% of adult-onset SLE
patients (p=NS) (Figure 2). In addition, 18% of childhood-onset SLE patients on belimumab
had at least 25% improvement in C3 levels and 44% had at least 25% decrease in antidsDNA values, three months after starting belimumab (p=0.0001), and this was maintained
at 6 months.
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Moreover, six months after initiation of belimumab, the mean prednisone equivalent dose
decreased from 17mg/day in childhood-onset SLE patients to 11mg/day. Steroids were
discontinued in 35% of childhood-onset SLE patients 6 months after belimumab initiation,
as compared with 11% of adult-onset SLE patients (p=0.002).
Safety

Author Manuscript

Data on adverse events and discontinuation of belimumab are presented in Table 3. No
deaths were reported and 32 patients (16%) discontinued belimumab after an average of
approximately nine months across all sites. The most common adverse effects and reasons
for discontinuation of therapy were infection and lack of response to belimumab. The most
serious infection was Group A Streptococcal bacteremia that occurred in one patient during
the time she was on treatment with belimumab. She had also had an elective cervical lymph
node biopsy performed 5 days prior to development of bacteremia. The lack of response to
belimumab included patients who demonstrated no improvement and/or worsening clinical
manifestations of disease while on belimumab, or developed new organ system involvement,
as judged by the treating physicians.
Of note, 4 patients developed features of neuropsychiatric lupus (NPSLE) while on
belimumab (one with stroke, one with psychosis, one with severe depression, and one with
new-onset seizures), and 2 patients who had existing NPSLE experienced worsening of
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disease while on belimumab (one with worsening depression, the other without specifics
reported). There were also 3 patients who developed or experienced worsening of lupus
nephritis over a year after initiation of therapy.
A total of 9 black patients discontinued belimumab, 2 due to exacerbation of renal disease, 2
due to development of or worsening neuropsychiatric disease, 1 due to arthritis flare, 1 due
to worsening myositis. Discontinuation reasons not related to lupus included 1 infusion
reaction, 1 who lost her insurance, and 1 who self-discontinued.

DISCUSSION

Author Manuscript

Belimumab is the first FDA-approved drug for the treatment of SLE in several decades and
marks a breakthrough in drug development in SLE (21). This study evaluates the efficacy
and safety of belimumab in 10 large academic clinical practices, and is the first report of the
efficacy and safety of belimumab in childhood-onset SLE.

Author Manuscript

Post-hoc analyses of the phase II belimumab trial data resulted in the development of a novel
SLE responder index, which served as a primary endpoint in the phase III program (22);
however, the stringency of this index precludes its practical use in routine clinical settings.
Therefore, the definition of clinical response used in this study is a simplified version of the
SRI; clinical response in this study was constructed around the treating physician’s
subjective assessment of at least 50% improvement clinical manifestations, similar to the
SLEDAI SRI-50 (23, 24). Our data suggest that clinical improvement in response to
belimumab may be detected as early as 3 months after initiation of therapy, and 51% of
patients show a response at 6 months. Improvements in complement and dsDNA antibody
levels were seen as early as 3 months after initiation of belimumab therapy and continued
through the 6-month follow-up.
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Since the results of the phase III trials, post-marketing analyses have consistently
demonstrated arthritis and mucocutaneous disease as common indications for the initiation
of belimumab therapy (25). Interestingly, less than 5% of the cohort as a whole were on
treatment with methotrexate prior to initiation of belimumab. Our data in a subset of patients
with childhood-onset SLE demonstrate similar trends; however, our data also show that over
80% of childhood-onset SLE patients were started on belimumab due to an inability to taper
existing steroids for treatment of lupus. Childhood-onset SLE patients may respond in as
quickly as 3 months after initiation of belimumab (41%) and a greater proportion responded
to belimumab (65%) than adult-onset SLE patients (45%) at 6 months (p=NS). The ability to
taper and often discontinue corticosteroids in childhood-onset SLE patients while on
treatment with belimumab may, in part, reflect a degree of non-compliance to oral
immunosuppressive medications in these patients.
Despite the small sample sizes in this study, serologically positive SLE patients responded
favorably to treatment with belimumab plus standard of care therapy. This is consistent with
the phase III belimumab trials (7, 8, 26). Moreover, given the higher prevalence of SLE in
black patients (27, 28), it is of interest to note that 67% of a subset of black patients
responded to belimumab therapy at 6 months. Subset analyses in phase III trials yielded
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lower response rates of black patients receiving belimumab versus those receiving placebo.
Our data demonstrate a better clinical response rate in blacks that is significantly higher than
those of other racial or ethnic subsets. Thus, results from clinical trials currently underway
focusing on black patients would be of utmost importance to individually tailor therapy.
Further studies in a larger population and for a longer time period will also be of benefit to
examine long-term outcomes and delineate adverse events. Ginzler et al (29) recently noted
that there was a reduced risk of SLE flare and continued improvement in clinical and
laboratory markers 7 years after initiation of belimumab therapy. Studies in patients with
lupus nephritis and/or NPSLE would also help define the role for belimumab and describe
the target population for optimal response. Although NPSLE patients have been excluded
from trials to date, there are ongoing trials using belimumab for patients with lupus nephritis
which will provide more definitive answers.
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Although data are limited, belimumab appears to be well-tolerated; 16% of patients
experienced an adverse event. This is a much lower rate of occurrence than reported by
Wallace et al (30) in a post-hoc analysis of the phase III trials. In the phase III trials, 6% of
patients developed depression, and 0.1% had suicidal ideation on belimumab therapy. In our
cohort, there were 6 patients who developed or had an exacerbation of existing NPSLE;
belimumab was discontinued in all these patients. Wallace et al (30) also noted a small
percentage of renal disease flare in patients on belimumab therapy. In addition, Dooley et al
(31) demonstrated in a post-hoc analysis of the phase III trial patients that of the 267 patients
with renal disease at the time of initiation of belimumab therapy, those on baseline
immunosuppressive medications or with serologic activity at baseline had greater renal
improvement on belimumab than those with placebo. They also note that renal flares and
reduction of renal symptomatology such as proteinuria and serologic activity appeared to
occur more frequently in patients on belimumab but was not statistically significant when
compared with placebo. Our data show that three patients developed or had an exacerbation
of lupus nephritis; all were childhood-onset SLE patients. However, in these patients, noncompliance with background standard-of-care lupus immunosuppressive medications may
have also played a role in worsening lupus nephritis.
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Moreover, given that we defined the lack of response to be no improvement and/or
worsening disease in any involved organ system, and/or development of disease in another
previously uninvolved organ system, it is possible that the inclusion of these patients in
calculating our response rate may reflect a lower rate of response than could be expected.
Other limitations include the short time of follow-up (6 months) in this study, and the lack of
comparison to a control group. This may have led us to overstate the efficacy of belimumab
in our population.
In summary, this study further substantiates the safety and efficacy of belimumab in the
treatment of SLE. The higher clinical response rate among black patients, with comparable
safety, is reassuring and should help alleviate concerns regarding the use of belimumab in
this racial group. Overall, belimumab appears to be well-tolerated; however, caution is
advised with its use in SLE patients with active NPSLE and/or renal disease until more data
are available. Moreover, our data suggest a larger role for belimumab as a corticosteroid-
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sparing agent in childhood-onset SLE given that 35% of patients were able to discontinue
steroid treatment after the addition of belimumab to standard-of-care lupus treatments. The
results of the clinical trials currently underway in pediatric SLE patients (under 18 years of
age) will be of interest in demonstrating the efficacy and safety of belimumab in this
population.
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Figure 1.

Author Manuscript

Response to belimumab in all patients with lupus at 3 and 6 months after initiation of
belimumab. Data were available on 158 patients at 3 months and 120 patients at 6 months of
treatment. Clinical response was defined as the treating physician’s impression of ≥50%
improvement in the initial manifestation(s) being treated and no worsening in other organ
systems. Improvement in serology included at least 25% decrease in anti-dsDNA level from
baseline.
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Figure 2.

Author Manuscript

Response to belimumab in patients with childhood-onset lupus at 3 and 6 months after
initiation of belimumab. Data were available on 35 patients at 3 months and 26 patients at 6
months of treatment. Clinical response was defined as the treating physician’s impression of
≥50% improvement in the initial manifestation(s) being treated and no worsening in other
organ systems. Improvement in serology included at least 25% decrease in anti-dsDNA level
from baseline.
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Table 1

Author Manuscript

All lupus patients: Baseline demographics, concomitant medications, and clinical manifestations driving
treatment with belimumab.
Baseline, n = 195

Author Manuscript
Author Manuscript

Female (%)

82

Mean age at diagnosis (range)

40.7 ± 13.7 years (4 to 65 years)

Disease duration at initiation of belimumab (n=151)

11.9 ± 8.1 years

Age at initiation of belimumab (range)

41.8 ± 12.7 years (15 to 73 years)

Race

%

Caucasian

61

Black

29

Asian

6

Other

2

Ethnicity

%

Hispanic/Latino

6

Clinical Manifestations

%

Arthritis

67

Rash

44

Constitutional

25

Inability to Taper Steroids

30

Renal

11

Neuropsychiatric lupus

9

More than two manifestations

67

Laboratory Manifestations

%

Hematologic

15

Hypocomplementemia

53

Elevated anti-dsDNA antibodies

37

Concomitant Medications

%

Antimalarials

73

Prednisone

74

Mean dose prednisone equivalent

12.2mg/day (range 5 to 50mg/day)

Immunosuppressive Agents

48

Mycophenolate

34

Azathioprine

21

Methotrexate

11

Angiotensin converting enzyme inhibitor

6

No SLE Medications

7

Author Manuscript

Abbreviations: anti-dsDNA, anti-double stranded DNA; SLE, systemic lupus erythematosus
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Table 2

Author Manuscript

Childhood-onset vs adult-onset lupus patients: Baseline demographics, concomitant medications, and clinical
manifestations driving treatment with belimumab.
Baseline

Author Manuscript
Author Manuscript

Childhood-onset SLE (n=39)

Adult-onset SLE (n=156)

Women (%)

90

92.3

Mean age at diagnosis

14 ± 4 years

33 ± 12 years

Disease duration at initiation of belimumab

12 ± 8 years

11 ± 7 years

Age at initiation of belimumab

27 ± 7 years *

45 ± 11 years *

Race

%

Caucasian

46

65

Black

48

25

Asian

6

6

Other

0

4

Ethnicity

%

%

Hispanic/Latino

12

4

Clinical Manifestations

%

%

Arthritis

46

70

Rash

36

45

Constitutional

13

27

Inability to Taper Steroids

82

28

Renal

15

11

Neuropsychiatric lupus

0

10

Laboratory Manifestations

%

%

Hematologic

5

12

Hypocomplementemia

59%

52%

Elevated anti-dsDNA antibodies

84%

29%

Concomitant Medications

%

%

Antimalarials

92

68

Prednisone

82 *

72

Mean dose prednisone equivalent

17mg/day *

11mg/day

Immunosuppressive Agents

72

53

Mycophenolate

49

33

Azathioprine

23

20

Methotrexate

0

14

Angiotensin converting enzyme inhibitor

8

4

No SLE Medications

0

4

Author Manuscript
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Table 3

Author Manuscript

Adverse events and reason(s) for discontinuation of belimumab.
Reasons for Discontinuation
Development/worsening neuropsychiatric lupus

6

Severe disease flares

4 (renal, arthritis)

Myocardial Infarction

1

Loss of Insurance

2

Infection

7 {most severe: pneumonia, Group A streptococcus bacteremia, axillary MRSA*}

Infusion Reaction

3

Elective Surgery

1

Patient Choice

2

No Clinical Response

6

Total (out of 195)

32 (16%)

Author Manuscript

Note:

*

Methicillin-Resistant Staphylococcus Aureus

Author Manuscript
Author Manuscript
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